NewsClick

NewsClick
  • हिन्दी
  • Politics
  • Economy
  • Covid-19
  • Science
  • Culture
  • India
  • International
  • Sports
  • Articles
  • Videos
search
menu

SUBSCRIBE AND SUPPORT

image/svg+xml
  • All Articles
  • Newsclick Articles
  • All Videos
  • Newsclick Videos
  • हिन्दी
  • Politics
  • Economy
  • Science
  • Culture
  • India
  • Sports
  • International
  • Africa
  • Latin America
  • Palestine
  • Nepal
  • Pakistan
  • Sri Lanka
  • US
  • West Asia
About us
Grievance Redressal Mechanism
Newsletter
Facebook - Newsclick Twitter - Newsclick Instagram - Newsclick Youtube - Newsclick RSS - Newsclick
close menu
  • Politics
  • Economy
  • Science
  • Culture
  • India
  • International
  • Sports
×
You deserve independent, critical media. Subscribe and Support

Soberana 2 : All

Primary tabs

  • All(active tab)
  • Articles
  • Videos
  • Interviews
  • Cuba’s anti-COVID-19 vaccine candidate, Soberana 02 of the Finlay Vaccine Institute (IFV), showed 91.2% efficacy with a third booster shot of Soberana Plus during the third phase of clinical trials. Photo: Endrys Correa Vaillant
    Peoples Dispatch
    Cuba’s Soberana 02 Vaccine Shows 91.2% Efficacy Against COVID-19
    10 Jul 2021
    With the historic achievement, two out of the five Cuban vaccine candidates, Soberana 02 with 91.2% and Abdala with 92.28% efficacy, are among the top 5 most effective anti-COVID-19 vaccines…
  • PD
    Beth Geglia
    Cuba Working on a ‘People’s Vaccine’: the US and the World Should get Behind it
    17 Mar 2021
    Amid growing accusations of vaccine hoarding by global north countries and patents blocking vaccine production, researcher and filmmaker Beth Geglia writes about the importance of supporting Cuba’s…
  • Vaccine
    European Secretariat of the International Peoples’ Assembly
    Vaccines: Patents or Life!
    12 Mar 2021
    Patents on vaccines and on new technologies against COVID-19 are the ball and chain in the race out of the global pandemic tunnel. Our lives are worth more than the profits of big pharmaceutical…
Newsletter
About us
Grievance Redressal Mechanism